Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding AG

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. The company develops innovative product candidates for various eye conditions.

Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

Following our recent Phase 2 RELIEF data for licaminlimab (also known as OCS-02), our novel anti-TNFα antibody eye drop candidate, the Oculis team had the opportunity to attend the 2024 @European Dry Eye Society Congress (#EuDEC 2024). We enjoyed the opportunity to discuss the data, which delivered further evidence to support the potential of our #PrecisionMedicine approach for the treatment of dry eye disease (#DED), a growing area of unmet need that affects nearly 40 million people in the US alone. 
 
The RELIEF trial was an exploratory study designed to achieve three specific objectives: to evaluate the efficacy of licaminlimab on the signs of DED, to confirm the TNFR1 genetic biomarker as a predictor of response and to select the primary sign efficacy endpoint for a future Phase 3 trial. The trial met all three of these objectives, with positive topline data complementing two prior successful Phase 2 studies, during which the TNFR1 genetic biomarker was identified as a predictor of high responders to therapy. Excitingly, improvement of multiple signs of DED were observed in the full trial population, with more pronounced effect in the subpopulation with a TNFR1-related genotype, consistent with earlier trial results and laying the groundwork for progression towards a Phase 3 study. 
 
For more information on the RELIEF topline results including important information on forward-looking statements, see our press release here: ur press release here: https://bit.ly/4bWdQw0

EURETINA and Oculis have come together to pay a lasting tribute to Professor Tadayoni’s legacy. In this effort, EURETINA has established the Ramin Tadayoni Award supported by Oculis. 

Professor Tadayoni was a world-renowned retina specialist who contributed greatly to the field of ophthalmology and to Oculis’ success as Retina Chair of the company’s Scientific Advisory Board and as Chief Scientific Officer, at the time of his unexpected passing earlier this year.

Throughout his career, Professor Tadayoni was highly committed to advancing retinal research and education. This annual award will combine both of these profound values by supporting the next generation of talented ophthalmologists who have demonstrated outstanding potential in retinal research and are driving forward innovation in the field. 

For additional details on this announcement, see our press release here: https://bit.ly/4ezIZY9

For more information about the Ramin Tadayoni Award, including eligibility requirements and how to apply, visit: https://lnkd.in/eFgZen6f

#eyehealth #ophthalmology #biotech #biopharma #eyedisease #education #researchgrant

It was a privilege to join leading ophthalmology experts during Eyecelerator @ASCRS 2024, to discuss the treatment landscape and recent advancements that are accelerating innovation.

At Oculis, our innovative and diversified pipeline continues to advance, and we remain laser-focused on delivering our key programs: OCS-01 in DME, OCS-02 in DED and OCS-05 in Acute Optic Neuritis. We are confident and excited as we move into a catalyst-rich 2024 and look forward to updating everyone on the upcoming RELIEF trial readout planned by end of Q2 and  the ACUITY trial readout of OCS-05 in Acute Optic Neuritis planned in Q4.

Thank you again to the conference organizers for an excellent event!

#eyehealth #ophthalmology #biotech #biopharma #eyecelerator #ASCRS

We are thrilled to welcome industry leaders, @Robert K. Warner and Dr. Arshad M. Khanani, to our Board of Directors. Mr. Warner, who brings substantial global and U.S. commercial leadership expertise, and Dr. Khanani, a world-renowned retina expert, will be invaluable additions to our already strong Board as we progress toward important inflection points. Welcome to Oculis! 
 
For full bios and additional detail on Oculis’ Annual General Meeting, including important information on forward-looking statements, see our press release here: https://bit.ly/3VkeKwz
 
#eyehealth #ophthalmology #biotech #biopharma #eyedisease #leadership

Great article from Ghislaine Bloch in Bilan Magazine featuring Oculis and the progress made to date to fulfill our mission of saving sight and improving eye care

On Sunday, Eric Donnenfeld, M.D., presented the positive topline results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place on April 5-8, 2024 in Boston, MA.
 
The Phase 3 OPTIMIZE-1 trial met its primary endpoints, demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgery. Topline data from the second Phase 3 OPTIMIZE-2 trial is anticipated in Q4 2024 and is expected to support NDA submission. If approved, OCS-01 would become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery. 
 
For additional details, including important information on forward-looking statements, see our press release here: https://bit.ly/3PTXbQV
 
#eyehealth #ophthalmology #biotech #biopharma #ASCRS

	Dec '20	Dec '21	Dec '22	Dec '23
net income	-14.79M -	-18.52M 25.25%	-38.64M 108.61%	-88.69M 129.52%
depreciation and amortization	228K -	235K 3.07%	299K 27.23%	287K 4.01%
deferred income tax	47K -	-1.05M 2,327.66%	580K 155.40%	4.32M 645%
stock based compensation	328K -	328K 0%	804K 145.12%	3.61M 348.76%
change in working capital	-451K -	-791K 75.39%	6.00M 858.28%	-12.99M 316.59%
accounts receivables
inventory
accounts payables	-649K -	30K 104.62%	3.04M 10,043.33%	3.73M 22.54%
other working capital	198K -	-821K 514.65%	2.96M 459.93%	-16.72M 665.82%
other non cash items	2.61M -	5.97M 128.98%	5.89M 1.44%	39.63M 572.98%
net cash provided by operating activities	-12.03M -	-13.82M 14.93%	-25.07M 81.37%	-53.84M 114.74%
investments in property plant and equipment	-19K -	-28K 47.37%	-3.55M 12,571.43%	-48K 98.65%
acquisitions net
purchases of investments				-54.16M -
sales maturities of investments
other investing activites
net cash used for investing activites	-19K -	-28K 47.37%	-3.55M 12,571.43%	-54.21M 1,427.93%
debt repayment	-98K -	-98K 0%	-159K 62.24%	-158K 0.63%
common stock issued			120K -	135.62M 112,912.50%
common stock repurchased
dividends paid
other financing activites	4.96M -	55.29M 1,015.43%	1.75M 96.83%	-5.79M 430.01%
net cash used provided by financing activities	4.86M -	55.19M 1,035.91%	1.71M 96.89%	129.67M 7,465.46%
effect of forex changes on cash	-12K -	-15K 25%	418K 2,886.67%	-3.08M 835.65%
net change in cash	-7.20M -	41.33M 673.96%	-26.49M 164.10%	18.54M 169.99%
cash at beginning of period	12.15M -	4.95M 59.25%	46.28M 834.51%	19.79M 57.24%
cash at end of period	4.95M -	46.28M 834.51%	19.79M 57.24%	38.33M 93.71%
operating cash flow	-12.03M -	-13.82M 14.93%	-25.07M 81.37%	-53.84M 114.74%
capital expenditure	-19K -	-28K 47.37%	-3.55M 12,571.43%	-48K 98.65%
free cash flow	-12.05M -	-13.85M 14.98%	-28.62M 106.61%	-53.89M 88.29%

COM:OCULIS

Oculis

Last Close

14.75

22/11 21:00

Market Cap

467.04M

Beta: -

Volume Today

39.61K

Avg: -

Preview